0 182

Cited 62 times in

Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer

Authors
 Sun Young Rha  ;  Yong Hwa Moon  ;  Hei Chul Jeung  ;  Yong Tae Kim  ;  Joo Hyuk Sohn  ;  Woo Ick Yang  ;  Chang Ok Suh  ;  Gwi Eon Kim  ;  Jae Kyung Roh  ;  Hyun Cheol Chung 
Citation
 BREAST CANCER RESEARCH AND TREATMENT, Vol.90(3) : 215-221, 2005 
Journal Title
 BREAST CANCER RESEARCH AND TREATMENT 
ISSN
 0167-6806 
Issue Date
2005
MeSH
Adult ; Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Antimetabolites, Antineoplastic/therapeutic use* ; Breast Neoplasms/drug therapy* ; Breast Neoplasms/pathology ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives* ; Deoxycytidine/therapeutic use* ; Female ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Infusions, Intravenous ; Middle Aged ; Neoplasm Metastasis* ; Salvage Therapy ; Survival Analysis ; Treatment Outcome
Keywords
breast cancer ; gemcitabine ; heavily pretreated ; monotherapy ; salvage
Abstract
PURPOSES: We evaluated the efficacy and tolerability of gemcitabine monotherapy in heavily pretreated, breast cancer patients as salvage chemotherapy. METHODS: A weekly infusion of gemcitabine at 850 mg/m2 for 30 min, for 3 of every 4 weeks, was introduced in advanced breast cancer patients who had failed previous doxorubicin and taxane based chemotherapy. There was no dose modification, and the treatment was delayed until the leukopenia was recovered with G-CSF support. The efficacy was evaluated every three cycles and the treatment was continued until either disease progression or 12 cycles. RESULTS: Of 41 enrolled patients, 38 were evaluable with a median age of 47. Total 178 cycles of gemcitabine was administered and the relative dose intensity was 89. The toxicity was mild with 12 of grade III neutropenia and 14 of grade III/IV thrombocytopenia without clinical symptoms. The response rate was 20 (8/38), comprising two complete and six partial responses. The median response duration and overall survival were 9 (2-25) and 11 months, respectively. The overall survival of 12 months was better in the third line patients than the 7 months in the fourth line treatment group. CONCLUSION: Gemcitabine monotherapy is effective and safe as salvage treatment in heavily pretreated, breast cancer patients.
Full Text
http://link.springer.com/article/10.1007%2Fs10549-004-2468-4
DOI
10.1007/s10549-004-2468-4
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
5. Research Institutes (연구소) > Cancer Metastasis Research Center (암전이연구센터) > 1. Journal Papers
Yonsei Authors
Kim, Gwi Eon(김귀언)
Roh, Jae Kyung(노재경)
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Moon, Yong Wha(문용화)
Suh, Chang Ok(서창옥)
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
Yang, Woo Ick(양우익) ORCID logo https://orcid.org/0000-0002-6084-5019
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
Jeung, Hei Cheul(정희철) ORCID logo https://orcid.org/0000-0003-0952-3679
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/147431
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse